BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25082363)

  • 21. Hospital burden of long-term genitourinary and gastrointestinal toxicity after radical radiotherapy for prostate cancer.
    Redmond EJ; Dolbec KS; Fawaz AS; Flood HD; Giri SK
    Surgeon; 2018 Jun; 16(3):171-175. PubMed ID: 28988618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.
    Karlsdóttir A; Johannessen DC; Muren LP; Wentzel-Larsen T; Dahl O
    Radiother Oncol; 2004 Apr; 71(1):43-53. PubMed ID: 15066295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique.
    Su AW; Jani AB
    Am J Clin Oncol; 2007 Jun; 30(3):215-9. PubMed ID: 17551295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
    Cheng JC; Schultheiss TE; Nguyen KH; Wong JY
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):351-7. PubMed ID: 18164841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comprehensive quality assurance program for personnel and procedures in radiation oncology: value of voluntary error reporting and checklists.
    Kalapurakal JA; Zafirovski A; Smith J; Fisher P; Sathiaseelan V; Barnard C; Rademaker AW; Rave N; Mittal BB
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):241-8. PubMed ID: 23561649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
    Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial.
    Beck M; Sassowsky M; Schär S; Mathier E; Halter M; Zwahlen DR; Hölscher T; Arnold W; Polat B; Hildebrandt G; Müller AC; Putora PM; Papachristofilou A; Hayoz S; Schär C; Li Q; Sumila M; Zaugg K; Guckenberger M; Ost P; Bosetti DG; Reuter C; Gomez S; Khanfir K; Aebersold DM; Ghadjar P; Pra AD
    Int J Radiat Oncol Biol Phys; 2022 May; 113(1):80-91. PubMed ID: 34990777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer.
    Sydes MR; Stephens RJ; Moore AR; Aird EG; Bidmead AM; Fallowfield LJ; Graham J; Griffiths S; Mayles WP; McGuire A; Stanley S; Warrington AP; Dearnaley DP;
    Radiother Oncol; 2004 Aug; 72(2):199-211. PubMed ID: 15297138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
    Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.
    Jani AB; Gratzle J
    Urology; 2005 Sep; 66(3):566-70. PubMed ID: 16140079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
    Kalakota K; Liauw SL
    Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature.
    Budäus L; Bolla M; Bossi A; Cozzarini C; Crook J; Widmark A; Wiegel T
    Eur Urol; 2012 Jan; 61(1):112-27. PubMed ID: 22001105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis.
    Kalakota K; Rakhno E; Pelizzari CA; Jani AB; Liauw SL
    Brachytherapy; 2010; 9(2):131-6. PubMed ID: 19853533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incremental changes verses a technological quantum leap: the additional value of intensity-modulated radiotherapy beyond image-guided radiotherapy for prostate irradiation.
    Ratnayake G; Martin J; Plank A; Wong W
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):503-10. PubMed ID: 25243269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria.
    Choo R; Pearse M; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):989-95. PubMed ID: 18436391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer.
    Jani AB; Parikh SD; Vijayakumar S; Gratzle J
    Urology; 2005 Jun; 65(6):1157-62. PubMed ID: 15913725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer.
    Hamstra DA; Stenmark MH; Ritter T; Litzenberg D; Jackson W; Johnson S; Albrecht-Unger L; Donaghy A; Phelps L; Blas K; Halverson S; Marsh R; Olson K; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1246-53. PubMed ID: 23265567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.